ClinicalTrials.gg
TerminatedNCT01452347RE-ALIGNUpdated Aug 6, 2014Results posted

Dabigatran Etexilate in Patients With Mechanical Heart Valves

A Phase 2 interventional study of warfarin 1mg and dabigatran etexilate intermediate dose in Heart Valve Diseases, sponsored by Boehringer Ingelheim. Terminated at 40 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-08-06.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Heart Valve Diseases with a site in Canada — 9 open to participants now, 14 under way, none of them phase 3. Heart Valve Diseases · Canada.

Enrollment
13th of 32
328 · median 245
Started
2011
with 3 others
Phase 2
3 of 39
none open now
Registered
15th of 39
by date
Lead sponsor
1 of 39
Boehringer Ingelheim

Among the 39 studies in Heart Valve Diseases with a site in Canada, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2011, is one of 3 in phase 2, and was the 15th registered.

Heart Valve Diseases

556 studies on the registry are indexed under Heart Valve Diseases; 166 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

9 of the 39 studies in Heart Valve Diseases with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Heart Valve Diseases with a site in Canada, or all of them as a file.
02

Study summary

To validate the dosing algorithm for dabigatran etexilate in patients receiving a mechanical heart valve.

03

Conditions studied

  • Heart Valve Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18-75
  2. Patients who have received a bileaflet mechanical heart valve

Exclusion criteria

Exclusion criteria:

  1. Prior valve surgery
  2. Uncontrolled hypertension
  3. severe renal impairment
  4. active liver disease
  5. increased risk of bleeding
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    Dabigatran etexilate

    Patient dose dependent on screening CrCl levels and TT

    Drug: dabigatran etexilate intermediate dose · Drug: dabigatran etexilate low dose · Drug: dabigatran etexilate high dose

  • Active comparator
    warfarin

    warfarin doses to maintain INR levels

    Drug: warfarin 1mg · Drug: warfarin 5mg · Drug: warfarin 3mg

Interventions

  • comparator warfarin

  • Drugdabigatran etexilate intermediate dose

    active treatment (medium)

  • Drugdabigatran etexilate low dose

    active treatment (low)

  • comparator warfarin

  • Drugdabigatran etexilate high dose

    active treatment (high)

  • comparator warfarin

06

What researchers measure

Primary outcomes

  1. Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1

    Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) . Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.

    Time frame: Week 1

  2. Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2

    Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.

    Time frame: Week 2

  3. Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4

    Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.

    Time frame: Week 4

  4. Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12

    Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1

    Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.

    Time frame: Week 1

  2. Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2

    Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.

    Time frame: Week 2

  3. Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4

    Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.

    Time frame: Week 4

  4. Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12

    Percentage of patients with observed Ctrough,ss value \< 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group.

    Time frame: Week 12

07

Results

Posted Aug 6, 2014
Limitations and caveats
This study was terminated prematurely due to safety concerns arising during conduct of the trial.

Participant flow

Participant flow — Overall Study
MilestoneDabigatran Etexilate (DE)Warfarin
Started16884
Completed15177
Not completed177
Withdrew: Adverse event21
Withdrew: Non compliance protocol20
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject33
Withdrew: Not treated63
Withdrew: Other reason not defined above20

Outcome measures

PrimaryComparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1

Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) . Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.

Time frame:
Week 1
Reported as:
Geometric mean · ng/mL
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1
ng/mLObservedPredicted
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 173.86 ± 43.999.52 ± 43.9
Statistical analysis
  • Observed vs Predicted · ANOVA · Adjusted geometric mean ratio: 74.22 · 95% CI 68.08 to 80.91The standard error of the mean is actually the geometric standard error. (Observed vs Predicted)
PrimaryComparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2

Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.

Time frame:
Week 2
Reported as:
Geometric mean · ng/mL
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2
ng/mLObservedPredicted
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 284.08 ± 40.299.55 ± 40.2
Statistical analysis
  • Observed vs Predicted · ANOVA · Adjusted geometric mean ratio: 84.46 · 95% CI 70.32 to 101.44The standard error of the mean is actually the geometric standard error. (Observed vs Predicted)
PrimaryComparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4

Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.

Time frame:
Week 4
Reported as:
Geometric mean · ng/mL
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4
ng/mLObservedPredicted
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4104.43 ± 34.3109.36 ± 34.3
Statistical analysis
  • Observed vs Predicted · ANOVA · Adjusted geometric mean ratio: 95.50 · 95% CI 88.69 to 102.84The standard error of the mean is actually the geometric standard error. (Observed vs Predicted)
PrimaryComparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12

Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE). (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.

Time frame:
Week 12
Reported as:
Geometric mean · ng/mL
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12
ng/mLObservedPredicted
Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12108.21 ± 59.8104.80 ± 59.8
Statistical analysis
  • Observed vs Predicted · ANOVA · Adjusted geometric mean ratio: 103.25 · 95% CI 86.40 to 123.40The standard error of the mean is actually the geometric standard error. (Observed vs Predicted)
SecondaryPercentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1

Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.

Time frame:
Week 1
Reported as:
Number · percentage of participants
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1
percentage of participantsPatients Evaluated
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 126.9
Statistical analysis
  • Patients Evaluated · Beta Function · p = <0.001 (Probability that P remains \< 10% are presented, where P=Percentage of patients with observed Ctrough,ss value \< 50 ng/mL)Probability calculated using Beta function \~B(1 + r, 1 + n - r),r=no. of patients(observed Ctrough,ss value \< 50 ng/mL), n=no. of patients evaluated
SecondaryPercentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2

Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2
percentage of participantsPatients Evaluated
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 219.2
Statistical analysis
  • Patients Evaluated · Beta Function · p = 0.05 (Probability that P remains \< 10% are presented, where P=Percentage of patients with observed Ctrough,ss value \< 50 ng/mL)Probability calculated using Beta function \~B(1 + r, 1 + n - r),r=no. of patients(observed Ctrough,ss value \< 50 ng/mL), n=no. of patients evaluated
SecondaryPercentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4

Percentage of patients with observed Ctrough,ss value \< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4
percentage of participantsPatients Evaluated
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 49.8
Statistical analysis
  • Patients Evaluated · Beta Function · p = 0.46 (Probability that P remains \< 10% are presented, where P=Percentage of patients with observed Ctrough,ss value \< 50 ng/mL)Probability calculated using Beta function \~B(1 + r, 1 + n - r),r=no. of patients(observed Ctrough,ss value \< 50 ng/mL), n=no. of patients evaluated
SecondaryPercentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12

Percentage of patients with observed Ctrough,ss value \< 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12
percentage of participantsPatients Evaluated
Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 127.4
Statistical analysis
  • Patients Evaluated · Beta Function · p = 0.65 (Probability that P remains \< 10% are presented, where P=Percentage of patients with observed Ctrough,ss value \< 50 ng/mL)Probability calculated using Beta function \~B(1 + r, 1 + n - r),r=no. of patients(observed Ctrough,ss value \< 50 ng/mL), n=no. of patients evaluated

Adverse events

Collected over From first intake of study drug until last intake of study drug plus 6 days (Up to 101 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate—19/162 (11.7%)64/162 (39.5%)
Warfarin—11/89 (12.4%)38/89 (42.7%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventDabigatran EtexilateWarfarin
Atrial fibrillationCardiac disorders5/1621/89
Pericardial effusionCardiac disorders5/1620/89
Wound infection staphylococcalInfections and infestations0/1621/89
Loss of consciousnessNervous system disorders0/1621/89
Prinzmetal anginaCardiac disorders0/1621/89
HypertensionVascular disorders1/1621/89
Back painMusculoskeletal and connective tissue disorders0/1621/89
Chest painGeneral disorders0/1621/89
Impaired healingGeneral disorders0/1621/89
Ejection fraction decreasedInvestigations0/1621/89
Most frequent other events
Showing 10 of 11
Most frequent other events
EventDabigatran EtexilateWarfarin
DiarrhoeaGastrointestinal disorders19/1622/89
Atrial fibrillationCardiac disorders11/1629/89
DyspepsiaGastrointestinal disorders15/1620/89
Pericardial effusionCardiac disorders8/1627/89
ConstipationGastrointestinal disorders10/1627/89
Pleural effusionRespiratory, thoracic and mediastinal disorders11/1623/89
CoughRespiratory, thoracic and mediastinal disorders8/1626/89
Oedema peripheralGeneral disorders10/1622/89
Urinary tract infectionInfections and infestations5/1625/89
DizzinessNervous system disorders3/1625/89

Baseline characteristics

Treated Set (TRT): The set of patients who received at least 1 dose of study medication

Age, Continuous
Age, Continuous(years)Dabigatran Etexilate (DE)WarfarinTotal
Mean56.3 ± 9.255.8 ± 10.256.2 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran Etexilate (DE)WarfarinTotal
Female602686
Male10255157
08

Study locations

40 sites
  • 1160.113.32007 Boehringer Ingelheim Investigational Site
    Brussel, Belgium
  • 1160.113.32003 Boehringer Ingelheim Investigational Site
    Bruxelles, Belgium
  • 1160.113.32002 Boehringer Ingelheim Investigational Site
    Genk, Belgium
  • 1160.113.32005 Boehringer Ingelheim Investigational Site
    Gent, Belgium
  • 1160.113.32001 Boehringer Ingelheim Investigational Site
    Leuven, Belgium
  • 1160.113.11002 Boehringer Ingelheim Investigational Site
    Edmonton, Alberta, Canada
  • 1160.113.11006 Boehringer Ingelheim Investigational Site
    Winnipeg, Manitoba, Canada
  • 1160.113.11001 Boehringer Ingelheim Investigational Site
    Saint John, New Brunswick, Canada
  • 1160.113.11009 Boehringer Ingelheim Investigational Site
    Hamilton, Ontario, Canada
  • 1160.113.11011 Boehringer Ingelheim Investigational Site
    London, Ontario, Canada
  • 1160.113.11012 Boehringer Ingelheim Investigational Site
    Newmarket, Ontario, Canada
  • 1160.113.11007 Boehringer Ingelheim Investigational Site
    Toronto, Ontario, Canada
  • 1160.113.42002 Boehringer Ingelheim Investigational Site
    Brno, Czech Republic
  • 1160.113.42005 Boehringer Ingelheim Investigational Site
    Hradec Kralove, Czech Republic
  • 1160.113.42003 Boehringer Ingelheim Investigational Site
    Olomouc, Czech Republic
  • 1160.113.42004 Boehringer Ingelheim Investigational Site
    Ostrava, Czech Republic
  • 1160.113.42001 Boehringer Ingelheim Investigational Site
    Prague 5, Czech Republic
  • 1160.113.45001 Boehringer Ingelheim Investigational Site
    Copenhagen, Denmark
  • 1160.113.45002 Boehringer Ingelheim Investigational Site
    Odense C, Denmark
  • 1160.113.33004 Boehringer Ingelheim Investigational Site
    Bron, France
  • 1160.113.33001 Boehringer Ingelheim Investigational Site
    Paris cedex 18, France
  • 1160.113.33002 Boehringer Ingelheim Investigational Site
    Pessac, France
  • 1160.113.33003 Boehringer Ingelheim Investigational Site
    Rennes Cedex 2, France
  • 1160.113.49001 Boehringer Ingelheim Investigational Site
    Dresden, Germany
  • 1160.113.49002 Boehringer Ingelheim Investigational Site
    Essen, Germany
  • 1160.113.49008 Boehringer Ingelheim Investigational Site
    Frankfurt am Main, Germany
  • 1160.113.49004 Boehringer Ingelheim Investigational Site
    Freiburg, Germany
  • 1160.113.49003 Boehringer Ingelheim Investigational Site
    Heidelberg, Germany
  • 1160.113.49010 Boehringer Ingelheim Investigational Site
    Witten, Germany
  • 1160.113.31001 Boehringer Ingelheim Investigational Site
    Amsterdam, Netherlands
  • 1160.113.31002 Boehringer Ingelheim Investigational Site
    Amsterdam, Netherlands
  • 1160.113.31004 Boehringer Ingelheim Investigational Site
    Breda, Netherlands
  • 1160.113.47002 Boehringer Ingelheim Investigational Site
    Bergen, Norway
  • 1160.113.47001 Boehringer Ingelheim Investigational Site
    Oslo, Norway
  • 1160.113.48004 Boehringer Ingelheim Investigational Site
    Gdansk, Poland
  • 1160.113.48003 Boehringer Ingelheim Investigational Site
    Warszawa, Poland
  • 1160.113.48001 Boehringer Ingelheim Investigational Site
    Wroclaw, Poland
  • 1160.113.46004 Sahlgrenska Universitetssjukhuset
    Göteborg, Sweden
  • 1160.113.46003 Skånes Universitetssjukhus Lund
    Lund, Sweden
  • 1160.113.46001 Akademiska Sjukhuset
    Uppsala, Sweden
09

References and documents

Publications

  • Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. doi: 10.1056/NEJMoa1300615. Epub 2013 Aug 31. PubMed 23991661 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2011
First posted
Oct 14, 2011
Start
Oct 2011
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Aug 6, 2014
Last update
Aug 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01452347
Responsible party
Sponsor
First posted
Oct 14, 2011
Start date
Oct 2011
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Aug 6, 2014
Last update
Aug 6, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion